

**JAPAN  
PERIPHERAL ARTERY DISEASE AND  
CRITICAL LIMB ISCHEMIA  
PREVALENCE AND INCIDENCE**

Mary L. Yost  
THE SAGE GROUP  
404-520-6652

THE SAGE GROUP, LLC  
23 Ridge Rd  
Beaufort SC 29907

Copyright Pending  
2017

All rights reserved, including the right of reproduction  
in whole or in part in any form.

## REFERENCES (FIRST AND LAST PAGES)

1. Ohsaka, H. , Shimada, K. , Fukao, K. , et al. Clinical and prognostic features in asymptomatic and symptomatic patients with arteriosclerosis obliterans. *World Journal of Cardiovascular Diseases* 2012; 2: 1-7.
2. Higashi Y, Miyata T, Shigematsu H, et al; SEASON Investigators. Baseline characterization of Japanese peripheral arterial disease patients-analysis of surveillance of cardiovascular events in antiplatelet-treated arteriosclerosis obliterans patients in Japan (SEASON). *Circ J* 2016; 80(3): 712-21.
3. Fujiwara T, Saitoh S, Takagi S, et al. Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. *Atherosclerosis*. 2004 Nov; 177(1): 83-8.
4. Yost ML. Critical limb ischemia Volume I. United States epidemiology. Atlanta (GA): THE SAGE GROUP; 2010.
5. Yost ML. Critical limb ischemia Volume I. United States epidemiology 2016 supplement. Beaufort (SC): THE SAGE GROUP; 2016.
6. Yost ML. Critical limb ischemia Volume II. Western Europe epidemiology. Atlanta (GA): THE SAGE GROUP; 2010.
7. Yost ML. Western Europe prevalence and incidence of peripheral artery disease and critical limb ischemia. Beaufort (SC): THE SAGE GROUP; 2017.
8. Yost ML. South America: diabetes, peripheral artery disease and critical limb ischemia. Atlanta (GA): THE SAGE GROUP; 2013.
9. Yost ML. Mexico: diabetes, peripheral artery disease and critical limb ischemia. Atlanta (GA): THE SAGE GROUP; 2014.
10. Yost ML. India Peripheral arterial disease, thromboangiitis obliterans & critical limb ischemia epidemiology and markets. Atlanta (GA) THE SAGE GROUP; 2009.
11. U.S. Census Bureau. International Data Base (IDB). Available at: <http://www.census.gov/population/international/data/idb/informationGateway.php>.
12. Maeda Y, Inoguchi T, Tsubouchi H, et al. High prevalence of peripheral arterial disease diagnosed by low ankle-brachial index in Japanese patients with diabetes: the Kyushu Prevention Study for Atherosclerosis. *Diabetes Res Clin Pract* 2008, Dec; 82(3):378-82.
13. Seki J, Ohashi M, Sato T, et al. Peripheral vascular disease in Japanese diabetics: screening by the Doppler ultrasonic technique. *Tohoku J Exp Med* 1983, Dec; 141 Suppl: 499-506.
14. Yokoyama H, Sone H, Honjo J, et al. Relationship between a low ankle brachial index and all-cause death and cardiovascular events in subjects with and without diabetes. *J Atheroscler Thromb*. 2014; 21(6):574-81.

72. Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007 Jan; 45 Suppl S: S5-67.
73. McDermott MM. Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia. *Circulation Research* 2015; 116(9): 1540-1550.
74. Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. *Circ Cardiovasc Qual Outcomes* 2010; 3:642-51.
75. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. *Circulation* 2009; 120: 2053-61.
76. Yost ML. *The real cost of peripheral artery disease.* Atlanta (GA): THE SAGE GROUP; 2011.
77. Conte MS, Bandyk DF, Clowes AW, et al. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. *J Vasc Surg* 2005; 42(3): 456-65.
78. Yost ML. *Critical limb ischemia United States prevalence and markets in patients and limbs* Atlanta (GA): THE SAGE GROUP; 2012.

## CONTACT INFORMATION

### Research

Mary L. Yost  
President and Senior Analyst  
Telephone (404) 520-6652  
[yost@thesagegroup.us](mailto:yost@thesagegroup.us)

### Marketing

Harrington Witherspoon  
Senior Vice President  
Marketing  
Telephone (404) 816-0746  
[witherspoon@thesagegroup.us](mailto:witherspoon@thesagegroup.us)